Alexion Pharma (ALXN) Tops Q3 EPS by 12c, Sales Miss; Bumps Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Tanker struck by projectile in Strait of Hormuz
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- AppLovin shares fall after court denies request against Unity
Alexion Pharma (ALXN) Threat From Amgen (AMGN) More Serious Than Previous Thought - Piper Jaffray
October 30, 2017 4:46 PM EDTPiper Jaffray maintains Overweight on Alexion Pharmaceuticals (NASDAQ: ALXN) price target of $170.00.
Analyst Chris Raymond says the threat from Amgen biosmiliar alternative to Soliris may be more credible and NT that previously suspected given what appears to be significant activity in Europe.... More
Alexion Pharmaceuticals (ALXN) PT Lowered to $159 at Stifel on 3Q Report; 'gMG Launch and P1/2 ALXN1210 Data Are Near-Term Catalysts'
October 27, 2017 11:11 AM EDTStifel lowered its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $159.00 (from $165.00) while maintaining a Hold rating, following the company's third quarter earnings report.
Analyst Stephen Willey notes a cautious outlook on the shares, commenting that "overall net product volume growth increased 9% y/y... More
Alexion Pharmaceuticals (ALXN) PT Raised to $122 at Jefferies Following 3Q
October 27, 2017 8:45 AM EDTJefferies raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $122.00 (from $121.00) while maintaining a Hold rating following the company's 3Q. ~In-line Soliris sales of ~$756M offset by lower non-GAAP OpEx and taxes, resulted in higher non-GAAP EPS of $1.44 (vs. consensus of... More
